Widening use of dexamethasone implant for the treatment of macular edema

Abstract: Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated in a biodegradable copolymer to release the active ingredient within the vitreous chamber for up to 6 months after an intravitreal injection, allowing a prolonged interval of efficacy between injections with a good safety profile. Various other ocular pathologies with inflammatory etiopathogeneses associated with macular edema have been treated by DEX implant, including neovascular age-related macular degeneration, Irvine–Gass syndrome, vasoproliferative retinal tumors, retinal telangiectasia, Coats’ disease, radiation maculopathy, retinitis pigmentosa, and macular edema secondary to scleral buckling and pars plana vitrectomy. We undertook a review to provide a comprehensive collection of all of the diseases that benefit from the use of the sustained-release DEX implant, alone or in combination with concomitant therapies. A MEDLINE search revealed lack of randomized controlled trials related to these indications. Therefore we included and analyzed all available studies (retrospective and prospective, comparative and non-comparative, randomized and nonrandomized, single center and multicenter, and case report). There are reports in the literature of the use of DEX implant across a range of macular edema-related pathologies, with their clinical experience supporting the use of DEX implant on a case-by-case basis with the aim of improving patient outcomes in many macular pathologies. As many of the reported macular pathologies are difficult to treat, a new treatment option that has a beneficial influence on the clinical course of the disease may be useful in clinical practice.

Keywords: macular edema, dexamethasone, intravitreal, implant, corticosteroids

Introduction

The sustained-release intravitreal (IV) 0.7 mg dexamethasone (DEX) implant (Ozurdex®, Allergan Pharmaceuticals, Irvine, CA, USA) is approved in Europe for the treatment of macular edema related to the following diseases: diabetic retinopathy, branch retinal vein occlusion or central retinal vein occlusion, and non-infectious uveitis.\(^1\)

DEX is one of the 3 most commonly used intraocular corticosteroids together with triamcinolone acetonide (TA) and fluocinolone acetonide. However, compared with these, DEX differs in its pharmacokinetics and pharmacodynamics properties due to certain biological effectiveness: different glucocorticoid receptor binding affinity (DEX > fluocinolone > triamcinolone) and different anti-inflammatory activities (DEX = fluocinolone and is 5 times more active than triamcinolone).\(^2\) The advantage of a DEX implant, containing micronized, preservative-free DEX 0.7 mg in a biodegradable copolymer of polylactic-co-glycolic acid (which eventually breaks down...
into carbon dioxide and water), is the release of the active ingredient within the vitreous chamber for up to 6 months after an IV injection. All these aforementioned features allow reduction in the frequency of injections with benefit in terms of hospital and patient resource saving, including diminished complications related to injection procedure (e.g., retinal detachment, endophthalmitis, lens iatrogenic injury, etc). However, in real life it has been shown that a shorter-interval re-treatment is required because of the loss of the drug’s effectiveness before 6 months, with a reported range varying from 4 to 5.9 months. Another relevant pharmacological aspect, as demonstrated by experimental studies, is the reduction of IV drugs half-life in vitrectomized eyes compared with non-vitrectomized ones, making their use ineffective. On the contrary, DEX implant has the advantage of maintaining the same half-life and, therefore, the same pharmacological properties in both vitrectomized and non-vitrectomized eyes.

Regarding complications related to the use of DEX implant, pivotal studies and real-life studies have confirmed a good safety profile with only a few complications: cataract progression in the range from 29.8% to 67.9%, closely related to the number of implants received, and an increase of intraocular pressure (IOP) >10 mmHg from baseline reported in a range of 15.4% and 27.7% of cases. There are several reviews collecting literature data about the approved use of sustained-release DEX implants. However, there are various ocular pathologies with inflammatory etiopathogeneses associated with macular edema, such as: neovascular age-related macular degeneration (nAMD); Irvine–Gass syndrome (IGS); vasoproliferative retinal telangiectasia (VPRs); retinal telangiectasia and Coats’ disease; radiation maculopathy; retinitis pigmentosa; macular edema secondary to scleral buckling and pars plana vitrectomy (PPV), all of which have been treated by DEX implant.

The aim of this review was to provide a systematic collection of all of the diseases that benefit from the use of the sustained-release DEX implant alone or in combination with concomitant therapies in order to provide a valuable therapy option for these diseases in clinical practice.

**Methods**

MEDLINE databases for the period 2009 to September 2016 were searched by using the medical subject heading “Dexamethasone intravitreal implant/Ozurdex” and the keywords “macular edema, age-related macular degeneration, Irvine–Gass, pseudophakic cystoid macular edema, post-operative macular edema, PPV, scleral buckling, retinitis pigmentosa, prostaglandin, radiation macular edema, telangiectasia.” Studies were limited to the English language. Because randomized controlled trials on these topics were lacking, all studies (retrospective and prospective, comparative and non-comparative, randomized and nonrandomized, single center and multicenter, and case reports) were analyzed. Aims, and anatomical and functional outcomes, and complications after DEX implant were analyzed.

**nAMD**

Approved first-line therapy for nAMD is based on the use of anti-vascular endothelial grow factor (VEGF) IV injections such as pegaptanib, ranibizumab, and aflibercept. However, there are patients who have a non-complete response to anti-VEGF injections as well as patients who, after an optimal functional and anatomical response, develop tachyphylaxis. The explanation for this incomplete response lies in the multifactorial pathogenesis of AMD, which involves VEGF, inflammation, and oxidative stress, as seen in histological studies performed on neovascular membranes after their surgical excision. Neovascular membrane growth in the sub-retinal space is stimulated by activated macrophages (and other inflammatory cells secreting cytokines) and enzymes that can damage the Bruch’s membrane. Therefore, inflammation is another potential target of nAMD treatment that could be counteracted by the use of corticosteroids.

Combination therapy consisting of anti-VEGF therapy and a corticosteroid relies on the use of drugs with different mechanisms of action, and could allow the reduction of anti-VEGF IV injection frequency and therefore, improve long-term efficacy and safety while reducing scarring results. Using combination therapies to treat nAMD dates back to photodynamic therapy (PDT), when it was associated with the IV TA injection. However, side effects due to IV TA, such as cataract progression and increased IOP, sometimes resistant to medical therapy, halted these procedures despite anatomical and functional benefits. Cataract surgery has been reported in around 45.2% of eyes that underwent triamcinolone injection, and ocular hypertension (IOP >21 mmHg) in around 44.6% of eyes, with IOP-lowering surgery required in 0.3% of eyes. The LuceDex study was the first study using the IV DEX injections (500 mg in 0.05 mL), followed by IV ranibizumab (4 monthly injections of 0.5 mg in 0.05 mL) that was compared with IV ranibizumab monotherapy (Group 2; total
Intra-, retro-, and peribulbar corticosteroids

Subcutaneous interferon

IV infliximab (anti-tumor necrosis factor-α)

PPV

Intra-, retro-, and peribulbar corticosteroids

The most likely physiopathological hypothesis for IGS is an inflammatory response instigated by the inflammatory mediators released during and after surgical procedures, causing alterations to the blood–retinal barrier. Many risk factors have been identified, such as posterior capsule rupture and vitreous loss, as well as the use of iris retractors, the presence of an epiretinal membrane, a vein occlusion, a history of uveitis or diabetes and the use of prostaglandin eye drops.26

First-line treatment for IGS involves the use of different therapies: topical nonsteroidal anti-inflammatory drugs (NSAIDs), oral acetazolamide, and topical corticosteroids. In patients resistant to such treatments, the following off-label treatment options have been tried:26–32

- IV anti-VEGF
- Subcutaneous interferon α2a injections
- IV infliximab (anti-tumor necrosis factor-α)
- Intra-, retro-, and peribulbar corticosteroids
- PPV

Several authors have evaluated the efficacy of DEX implant for chronic IGS31–45 (Table 2).

Most of the studies had a 6-month follow-up; they showed a significant improvement in BCVA and a significant reduction in CMT with 1 DEX implant. Two prospective studies38,43 of DEX compared with IVTA showed similar functional effects and anatomical effects: one found a lower incidence of ocular hypertension in the DEX group (at 6 months 0% vs 20%, P=0.044).

A retrospective long-term study44 that included 58 cases of IGS in a total of 100 eyes found that efficacy was maintained at 24 months, after a mean number of 1.77 DEX implants in the first year and 1.70 in the second year. At 24 months, an IOP >25 mmHg was found in 6.2% of the patients, all treated with hypotensive eye drops and not requiring filtering surgery.44

VPRTs

Several approaches have been used to treat VPRTs, including cryotherapy, laser photoacoagulation, PDT, IV anti-VEGF, plaque brachytherapy, and PPV.45–47

VPRTs treated by DEX and PDT were reported in 3 cases48 (Table 3). Total involution of the tumor was reported within 2 months and regression of exudates continued for several months, leaving fibrotic scar tissue in the inferior half of the retina.48

Retinal telangiectasia and Coats’ disease

Retinal telangiectasia

Yannuzzi et al49 have recently classified different forms of idiopathic macular telangiectasia: aneurismal telangiectasia, idiopathic perifoveal telangiectasia, and occlusive telangiectasia. Although several approaches have been suggested for the treatment of idiopathic macular telangiectasia (including laser photoacoagulation,50 PDT,51 IV anti-VEGF,52 PPV53), no treatment has yet been shown to provide a consistent effect on visual acuity. Also, corticosteroids have been used to treat these vascular pathologies due to their biological effect54 and DEX implant can be assumed to be an useful therapeutic device.55,56 which can also be administered in pediatric patients57 (Table 4).

In these cases, with a longer follow-up, multiple DEX implants were performed, at each time successfully (leading to BCVA improvement and CMT reduction).56–58

Coats’ disease

In Coats’ disease, ablative therapy by laser photoacoagulation and cryotherapy is the gold standard of treatment59 with photoacoagulation preferred over cryotherapy in cases with little or no subretinal fluid.57 IV therapies such as anti-VEGF and steroids could be used to improve anatomic and visual outcomes58,59 in particular, in combination with ablative therapies. IV corticosteroids, including DEX implant60–62
## Table 1 Published studies on the use of DEX implant for age-related macular degeneration

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>No of eyes</th>
<th>Previous treatment</th>
<th>Treatment</th>
<th>Follow-up</th>
<th>Retreatment</th>
<th>BCVA</th>
<th>CMT</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calvo et al²²</td>
<td>Retrospective</td>
<td>7 refractory</td>
<td>3 anti-VEGF</td>
<td>1 DEX + ranibizumab monthly</td>
<td>6 months</td>
<td>2 DEX (28.5%)</td>
<td>From 0.53±0.13 logMAR to 3 months: 0.45±0.3 (P=0.23)</td>
<td>From 273.14±50.94 µm to 3 months: 241.5±36.6 µm; (P=0.04)</td>
<td>3 ocular hypertension (42.8%) (27–32 mmHg)</td>
</tr>
<tr>
<td>Kuppermann et al²³</td>
<td>Prospective</td>
<td>243</td>
<td>115 naïve:</td>
<td>58 DEX + ranibizumab PRN</td>
<td>6 months</td>
<td>3.15 DEX + ranibizumab PRN</td>
<td>Naïve Change from baseline: DEX: +0.3 to +2.7 L Sham: −0.5 to +2.6 L</td>
<td>Naïve Change from baseline: DEX: −12.6±9.4 µm Sham: −34.7±106.6 µm (P&lt;0.05)</td>
<td>DEX 18.2% IOP ≥25 mmHg (P=0.002)</td>
</tr>
<tr>
<td></td>
<td>multicenter randomized</td>
<td></td>
<td>20 prev treatment</td>
<td>65 DEX + ranibizumab vs 63 sham + ranibizumab PRN</td>
<td>6 months</td>
<td>3.37 sham + ranibizumab</td>
<td>Prev treatment Change from baseline: DEX: −0.4 to +2.4 L Sham: −0.3 to +2.6 L</td>
<td>Prev treatment Change from baseline: DEX: −1.74±54.4 µm Sham: +6.84±8.49 µm (P=ns)</td>
<td>Sham 5.1%</td>
</tr>
<tr>
<td>Rezar-Dreindl et al²⁴</td>
<td>Prospective</td>
<td>40</td>
<td>NR</td>
<td>20 ranibizumab</td>
<td>12 months</td>
<td>7.95 ranibizumab P=0.042</td>
<td>Change from baseline: 10.8±13.2 L 3.0±10.5 L (P=0.37)</td>
<td>Change from baseline: 31.7±17.5% to 13.3±27.0% (P=0.236)</td>
<td>9% cataract surgery 0% IOP &gt;30 mmHg 15% IOP &gt;30 mmHg</td>
</tr>
<tr>
<td></td>
<td>randomized</td>
<td></td>
<td>5.6±3.4 ranibizumab</td>
<td>20 ranibizumab + DEX</td>
<td>12 months</td>
<td>6.7±4.4 ranibizumab</td>
<td>From 485 µm to 6 months: 426 µm 12 months: 453 µm (P=0.38)</td>
<td>From 439 µm to 6 months: 375 µm 12 months: 368 µm</td>
<td>33% cataract surgery 15% IOP &gt;30 mmHg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NR</td>
<td>5 ranibizumab</td>
<td>6 months</td>
<td>6.2±2.3</td>
<td>Change from baseline: 10.8±13.2 L 3.0±10.5 L (P=0.37)</td>
<td>Change from baseline: 31.7±17.5% to 13.3±27.0% (P=0.236)</td>
<td>9% cataract surgery 0% IOP &gt;30 mmHg 15% IOP &gt;30 mmHg</td>
</tr>
<tr>
<td>Chaudhary et al²⁵</td>
<td>Prospective</td>
<td>10</td>
<td>NR</td>
<td>5 ranibizumab + DEX</td>
<td>6 months</td>
<td>5.8±1.8 (P=0.766)</td>
<td>Change from baseline: 10.8±13.2 L 3.0±10.5 L (P=0.37)</td>
<td>Change from baseline: 31.7±17.5% to 13.3±27.0% (P=0.236)</td>
<td>9% cataract surgery 0% IOP &gt;30 mmHg 15% IOP &gt;30 mmHg</td>
</tr>
</tbody>
</table>

**Abbreviations:** BCVA, best corrected visual acuity; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; Naïve, previously untreated; NR, not reported; ns, not significant; prev treatment, previously treated; PRN, pro re nata; VEGF, vascular endothelial growth factor.
### Table 2 Published studies on the use of DeX implant for Irvine–Gass syndrome

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>No of eyes</th>
<th>Previous treatment</th>
<th>Treatment</th>
<th>Follow-up</th>
<th>Retreatment</th>
<th>BCVA</th>
<th>CMT</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Williams et al&lt;sup&gt;33&lt;/sup&gt;</td>
<td>Prospective multicenter randomized</td>
<td>41 uveitis + IGS (27)</td>
<td>Laser Medical therapy</td>
<td>DEX 0.7 mg or DEX 0.35 mg observation</td>
<td>6 months</td>
<td>NR</td>
<td>53.8% improvement ≥ 10 L after 3 months (P=0.029)</td>
<td>NR</td>
<td>31% IOP &gt;25 mmHg (0.7 mg)</td>
</tr>
<tr>
<td>Meyer and Schönfeld&lt;sup&gt;34&lt;/sup&gt;</td>
<td>Case report</td>
<td>1</td>
<td>3 IVT 0.4 mg dexamethasone CAIs</td>
<td>I DEX</td>
<td>4 months</td>
<td>NR</td>
<td>From 0.30 to 0.8 (for at least 3 months)</td>
<td>From 393 µm to 212 µm (P=0.001)</td>
<td>NR</td>
</tr>
<tr>
<td>Dutra Medeiros et al&lt;sup&gt;35&lt;/sup&gt;</td>
<td>Retrospective</td>
<td>9</td>
<td>Topical NSAIDs Corticosteroids IVT anti-VEGF IVT TA</td>
<td>1 DeX</td>
<td>6 months</td>
<td>NR</td>
<td>From 0.62±0.15 logMAR to 1 month: 0.47±0.21 (P=0.008)</td>
<td>From 542.2±134.7 µm to 319.2±60.96 µm (P=0.002)</td>
<td>NR</td>
</tr>
<tr>
<td>Brynskov et al&lt;sup&gt;36&lt;/sup&gt;</td>
<td>Case report</td>
<td>1</td>
<td>TA Sub-Tenon's S Ranibizumab IVT</td>
<td>DEX</td>
<td>12 (187 days later)</td>
<td>Second DEX</td>
<td>First DEX: from 78 ETDRS letters to 76</td>
<td>219 µm (after 83 days)</td>
<td>NR</td>
</tr>
<tr>
<td>Fenicia et al&lt;sup&gt;37&lt;/sup&gt;</td>
<td>Case report</td>
<td>1 patient (2 eyes)</td>
<td>RE: topical NSAIDs Oral indomethacin 3 periocular methylprednisolone RE: topical NSAIDs Oral indomethacin Ranibizumab IVT</td>
<td>RE: DEX + Ranibizumab IVT (84 days later) + I DEX (2 months later IVT ranibizumab)</td>
<td>NR</td>
<td>LE: DEX</td>
<td>RE: from 20/70 to 50 days 20/20</td>
<td>−369 µm after 7 days</td>
<td>NR</td>
</tr>
<tr>
<td>Dang et al&lt;sup&gt;38&lt;/sup&gt;</td>
<td>Prospective, nonrandomized, comparative</td>
<td>18</td>
<td>Topical steroids Topical NSAIDs</td>
<td>DEX</td>
<td>6 months</td>
<td>NR</td>
<td>1 month: VAI 44% P=0.625 vs TA</td>
<td>1 month: −175 µm (mean change), P=0.783 vs TA</td>
<td>DEX</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>No of eyes</th>
<th>Previous treatment</th>
<th>Treatment</th>
<th>Follow-up</th>
<th>Retreatment</th>
<th>BCVA</th>
<th>CMT</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furino et al(^a)(^b)</td>
<td>Retrospective</td>
<td>11</td>
<td>NR</td>
<td>I DEX</td>
<td>6.27±0.47</td>
<td>NR</td>
<td>From 20/40 to 20/22 (P&lt;0.0001)</td>
<td>From 462±100 µm to 276±8 µm (P&lt;0.0001)</td>
<td>NR</td>
</tr>
<tr>
<td>Al Zamil(^c)(^d)</td>
<td>Retrospective</td>
<td>11</td>
<td>Oral CAIs</td>
<td>I DEX</td>
<td>6</td>
<td>NR</td>
<td>From 0.58±0.17 logMAR to 1 month: 0.37±0.16 logMAR (P=0.008)</td>
<td>From 513.8±134.9 µm to 1 month: 371.6±91.9 (P=0.001)</td>
<td>NR</td>
</tr>
<tr>
<td>Khurana et al(^e)</td>
<td>Prospective case series</td>
<td>6</td>
<td>Topical NSAIDs</td>
<td>I DEX</td>
<td>NR</td>
<td>6 months: +14 L (P=0.03)</td>
<td>6 months: +14 L (P=0.03)</td>
<td>6 months: −72 µm (mean change) (P=0.004)</td>
<td>NR</td>
</tr>
<tr>
<td>Ortega-Evangelico and Diago Sempere(^f)</td>
<td>Retrospective</td>
<td>4</td>
<td>NR</td>
<td>I DEX</td>
<td>6</td>
<td>From 0.3 to 1 month: 0.575 logMAR (mean)</td>
<td>From 41.4 µm to 1 month: 330.25 µm (mean change)</td>
<td>NR</td>
<td></td>
</tr>
</tbody>
</table>
DeX implant for the treatment of macular edema

Mylonas et al\(^\text{43}\) Prospective randomized 29 NR 14 IVTA 6 19 second IVTA From 63±13 L to 1 month: 73±11 L (P=0.001) 3 months: 73±11 L (P=0.001) 6 months: 71±13 L (P=0.001) From 516±13 L to 1 month: 73±11 L (P=0.001) 3 months: 73±11 L (P=0.001) 6 months: 71±13 L (P=0.001)

From 60±10 L to 1 month: 73±10 L (P<0.001) 3 months: 72±11 L (P<0.001) 6 months: 66±13 L (P=0.009) 1 month: P=0.86 vs DeX 3 months: P=0.80 vs DeX 6 months: P=0.80 vs DeX

15 DEX From 548±10 μm to 1 month: 537±69 μm (P<0.001) 3 months: 391±102 μm (P<0.001) 6 months: 504±159 μm (P=0.05) 1 month: P=0.92 vs DeX 3 months: P=0.94 vs DeX 6 months: P=0.01 vs DeX

From 516±121 μm to 1 month: 355±59 μm (P<0.001) 3 months: 389±89 μm (P<0.001) 6 months: 365±74 μm (P=0.002)

From 548±110 μm to 1 month: 357±69 μm (P<0.001) 3 months: 391±102 μm (P<0.001) 6 months: 504±159 μm (P=0.05) 1 month: P=0.92 vs DeX 3 months: P=0.94 vs DeX 6 months: P=0.01 vs DeX

From 20/40 to 1 month: 20/30 NR

EPISODIC 2 Retrospective 58 IGS of 100 overall NR 1 DEX 24 months 1.7 first year (25 eyes) 1.657 second year Baseline mean 58.5±15.6 L 18 months: 66.9±18.3 L (P=0.0035) 24 months: 62.3±14.3 L (P<0.001) Baseline 518.13±117.2 μm 18 months: 346.7±115.7 μm (P<0.001) 24 months: 340.2±116 μm (P<0.001)

1 DEX 6 months NR From 20/40 to 1 month: NR 20/30

Abbreviations: BCVA, best corrected visual acuity; CAIs, carbonic anhydrase inhibitors; CMT, central macular thickness; DeX, dexamethasone implant; ETDRS, Early Treatment Diabetic Retinopathy Study; IGS, Irvine-Gass syndrome; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone acetonide; L, ETDRS letters; LE, left eye; NR, not reported; NSAIDs, nonsteroidal anti-inflammatory drugs; RE, right eye; TA, triamcinolone acetonide; VAI, visual acuity improvement ≥10 L; VEGF, vascular endothelial growth factor.
have been used to reduce intraocular inflammation, tighten capillary walls, and suppress cell proliferation, also having anti-VEGF properties.58 (Table 5).

In one case, DEX implant led to a resolution of the exudative retinal detachment allowing laser photoagulation of telangiectatic vessels.53 In other cases, final BCVA was influenced by subfoveal fibrosis, present at the time of the treatment59 or existing over a long-term.60

**Radiation maculopathy**

Several treatments have been proposed for radiation maculopathy, including laser photoagulation, PDT, pericentral injection of TA, IV anti-VEGF and, most recently, DEX implant (Table 6).63-68 All of these studies demonstrated a significant anatomical benefit with DEX implant in cases of recalcitrant radiation macular edema, with significant changes in visual acuity in most of the cases. Two comparative studies65,67 comparing DEX implant with anti-VEGF therapy, found no difference in outcomes, and a reduction in the number of injections in DEX-treated eyes.65

IOP increased in some eyes, all successfully treated by topical hypotonizing therapy. Cataract development in these cases could be caused by DEX or the radiation therapy.

**Retinitis pigmentosa**

The exact pathogenesis of macular edema, whether it is related to chronic and low-grade inflammatory process or to autoimmune process as antiretinal antibodies or to the failure of the retinal pigment epithelium pumping mechanism, is unknown as yet.71 Treatments attempted include topical and systemic administration of CAI, NSAIDs, retinal laser photocoagulation, vitrectomy surgery, and IV anti-VEGF.72 Also, IV corticosteroids injections have been performed as these drugs may modulate the inflammatory mediators and the autoimmune process.74-76

The studies reporting on the use of DEX in macular edema related to retinitis pigmentosa consist of case report studies, which include only a few eyes (Table 7).77-80 Nevertheless, an anatomical and functional improvement has been shown, but a relapse of macular edema occurred before 6 months from the implant and an additional DEX was required in some cases.77,78 DEX implant proved to be safe with an IOP rise >21 mmHg recorded in only one eye.78

---

**Table 3** DEX in vasoproliferative retinal tumors

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>No of eyes</th>
<th>Previous treatment</th>
<th>Treatment</th>
<th>Follow-up</th>
<th>Retreatment</th>
<th>BCVA</th>
<th>CMT</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cebeçi et al46</td>
<td>Case report</td>
<td>3</td>
<td>IVT BEV DEX</td>
<td>Laser photoagulation</td>
<td>12 months</td>
<td>I DEX + PDT (1 week after)</td>
<td>From 20/25 to 20/40</td>
<td>NR</td>
<td>I subcapsular cataract</td>
</tr>
</tbody>
</table>

Abbreviations: BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IVT, intravitreal; NR, not reported; PDT, photodynamic therapy.

---

**Table 4** Published studies on the use of DEX implant for retinal telangiectasia

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>No of eyes</th>
<th>Previous treatment</th>
<th>Treatment</th>
<th>Follow-up</th>
<th>Retreatment</th>
<th>BCVA</th>
<th>CMT</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sandali et al 55</td>
<td>Case report</td>
<td>I</td>
<td>3 BEV IVT</td>
<td>DEX</td>
<td>15 months</td>
<td>2 DEX</td>
<td>From 20/32 to 1 month: 20/20</td>
<td>From 398 µm to 1 month: 250 µm</td>
<td>NR</td>
</tr>
<tr>
<td>Loufi et al 54</td>
<td>Case report</td>
<td>I</td>
<td>3 BEV IVT</td>
<td>DEX</td>
<td>NR</td>
<td>3 DEX</td>
<td>From 0.3 to 0.59 logMAR: 6 weeks after 1st DEX; from 0.3 to 0.64 logMAR: 6 weeks after 2nd DEX; from 0.3 to 0.78 logMAR: 2 weeks after 3rd DEX</td>
<td>From 397 µm to 286 µm: 1° DEX; from 397 µm to 279 µm: 2° DEX; from 397 µm to 279 µm: 3° DEX</td>
<td>NR</td>
</tr>
<tr>
<td>Lei and Lam 62</td>
<td>Retrospective</td>
<td>I</td>
<td>8 ranibizumab</td>
<td>DEX</td>
<td>17 months</td>
<td>4 DEX</td>
<td>From 1 to 52 weeks: 0.5 logMAR: From 607 µm to 52 weeks: 346 µm</td>
<td>From 279 µm to 279 µm: 2° DEX; from 279 µm to 279 µm: 3° DEX</td>
<td>NR</td>
</tr>
</tbody>
</table>

Abbreviations: BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IVT, intravitreal; IVTA, intravitreal triamcinolone acetonide; NR, not reported.
Table 5 DEX implant in Coats’ disease

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>No of eyes</th>
<th>Previous treatment</th>
<th>Primary treatment</th>
<th>Follow-up</th>
<th>Retreatment</th>
<th>BCVA</th>
<th>CMT</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saatci et al[60]</td>
<td>Case report</td>
<td>2</td>
<td>5 ranibizumab IVT + laser photoagulation in 1 eye</td>
<td>DEX in one patient DEX + laser photoagulation in the other patient</td>
<td>12 months</td>
<td>NR</td>
<td>Unchanged</td>
<td>NR</td>
<td>IOP rise &gt;25 mmHg in both eyes</td>
</tr>
<tr>
<td>Martínez-Castillo et al[61]</td>
<td>Case report</td>
<td>1</td>
<td>None</td>
<td>DEX + laser photoagulation</td>
<td>12 months</td>
<td>NR</td>
<td>From 20/200 to 20/25</td>
<td>NR</td>
<td>None</td>
</tr>
<tr>
<td>Lei and Lam[62]</td>
<td>Retrospective chart review</td>
<td>1</td>
<td>3 BEV IVT + laser photoagulation</td>
<td>DEX</td>
<td>16 months</td>
<td>3 DEX</td>
<td>From 1.3 to 52 weeks: 1.8 logMAR</td>
<td>52 weeks: 589 µm</td>
<td>None</td>
</tr>
</tbody>
</table>

**Abbreviations:** BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; IVT, intravitreal; NR, not reported.

Table 6 Published studies on the use of DEX implant for radiation maculopathy

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>No of eyes</th>
<th>Previous treatment</th>
<th>Primary treatment</th>
<th>Follow-up</th>
<th>Retreatment</th>
<th>BCVA</th>
<th>CMT</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baillif et al[63]</td>
<td>Retrospective</td>
<td>5</td>
<td>None</td>
<td>DEX</td>
<td>6.4 months</td>
<td>3 eyes: 1 DEX 2 eyes: 2 DEX</td>
<td>From 41 L to 2 months: 47 L</td>
<td>From 487.1 µm to 331.2 µm</td>
<td>1 eye IOP &gt;25 mmHg</td>
</tr>
<tr>
<td>Caminal et al[64]</td>
<td>Retrospective</td>
<td>12</td>
<td>2 laser 2 VEGF IVT 5 laser + anti-VEGF IVT</td>
<td>DEX</td>
<td>8.2±7.8 months</td>
<td>1 eye: 2 DEX</td>
<td>From 1±0.58 to 0.8±1.58 logMAR (P=0.091)</td>
<td>From 416±263 to 254±170 µm (P=0.016)</td>
<td>1 eye cataract</td>
</tr>
<tr>
<td>Russo et al[65]</td>
<td>Retrospective comparative</td>
<td>16</td>
<td>NR</td>
<td>8 DEX</td>
<td>Range 7–52 months</td>
<td>2.4±0.9 DEX (24 months) (P=0.018 vs ranibizumab)</td>
<td>DEX: from 0.45±0.18 to last follow-up: 0.27±0.15 logMAR (P=0.011)</td>
<td>From 437±71 µm to last follow-up: 254±44 µm (P=0.012)</td>
<td>1 eye IOP rise</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8 ranibizumab IVT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
### Table 6 (Continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>No of eyes</th>
<th>Previous treatment</th>
<th>Primary treatment</th>
<th>Follow-up</th>
<th>Retreatment</th>
<th>BCVA</th>
<th>CMT</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bui et al56</td>
<td>Retrospective</td>
<td>2</td>
<td>16 BEV IVT +4 IVTA</td>
<td>DEX</td>
<td>NR</td>
<td>2 DEX</td>
<td>From 20/60 Snellen to 3 months: unchanged</td>
<td>From 456 to 238 µm after first DEX, 277 µm after second DEX From 618 to 336 µm</td>
<td>1 cataract surgery</td>
</tr>
<tr>
<td>Srour et al57</td>
<td>Retrospective comparative</td>
<td>5 DEX</td>
<td>None</td>
<td>DEX</td>
<td>At least 12 months</td>
<td>1–2 DEX BEV (range 1–10) IVTA (range 1–3)</td>
<td>From 20/60 Snellen to 3 months: unchanged</td>
<td>From 440 µm to 4 weeks 265 µm (P=0.049)</td>
<td>2 IOP rise</td>
</tr>
<tr>
<td>Ahn et al58</td>
<td>Case report</td>
<td>2 eyes of one patient</td>
<td>38 BEV</td>
<td>BEV</td>
<td>35 IVTA</td>
<td>IVTA</td>
<td>From 20/100 Snellen to 2–4 weeks 20/50 to 10 weeks 20/80 Snellen to 14–17 weeks: 20/100 Snellen</td>
<td>From 616 µm to 4 weeks 399 µm (P=0.034)</td>
<td>1 eye IOP &gt;25 mmHg</td>
</tr>
<tr>
<td>Saatci et al59</td>
<td>Case report</td>
<td>2 eyes of one patient</td>
<td>BEV IVT in 3 eyes BEV IVT + panretinal laser photococoagulation and IVTA in 1 eye</td>
<td>DEX</td>
<td>NR</td>
<td>NR</td>
<td>From 20/100 Snellen to 2–4 weeks 20/50 to 10 weeks 20/80 Snellen to 14–17 weeks: 20/100 Snellen</td>
<td>From 440 µm to 4 weeks 265 µm (P=0.049)</td>
<td>2 IOP rise</td>
</tr>
<tr>
<td>Tarmann et al60</td>
<td>Retrospective</td>
<td>4</td>
<td>16 BEV IVT +4 IVTA</td>
<td>DEX</td>
<td>NR</td>
<td>2 DEX</td>
<td>From 20/60 Snellen to 3 months: unchanged</td>
<td>None</td>
<td>2 IOP rise</td>
</tr>
</tbody>
</table>

**Abbreviations:** BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone acetonide; NR, not reported; VEGF, vascular endothelial growth factor.

### Table 7 DEX implant in retinitis pigmentosa

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>No of eyes</th>
<th>Previous treatment</th>
<th>Treatment</th>
<th>Follow-up</th>
<th>Retreatment</th>
<th>BCVA</th>
<th>CMT</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Srour et al57</td>
<td>Retrospective</td>
<td>4</td>
<td>CAIs in all cases subtenon TA 1 case NSAIDs in 2 cases</td>
<td>DEX</td>
<td>6 months 2 DEX in 2 eyes after 3 months</td>
<td>From 20/160 to 6 months: 20/125 after 1 DEX</td>
<td>From 443±185 µm to 6 months: 30±124 µm after 1 DEX</td>
<td>None</td>
<td>2 IOP rise</td>
</tr>
<tr>
<td>Ahn et al58</td>
<td>Case report</td>
<td>2 eyes of one patient</td>
<td>CAIs Anti-VEGF IVT</td>
<td>DEX</td>
<td>12 months 2 DEX in 1 eye 6 months after DEX</td>
<td>From 20/100 to 12 months: 20/60 RE From 20/150 to 12 months: 20/100 LE</td>
<td>From 616 µm to 12 months: 531 µm RE From 681 µm to 12 months: 499 µm LE</td>
<td>None</td>
<td>2 IOP rise</td>
</tr>
<tr>
<td>Saatci et al59</td>
<td>Case report</td>
<td>2 eyes of one patient</td>
<td>Topical CAIs</td>
<td>I DEX</td>
<td>7 months NR</td>
<td>From 2/10 to 1 week: 4/10 both eyes 3 months: 2/10 both eyes</td>
<td>None</td>
<td>2 IOP rise</td>
<td></td>
</tr>
<tr>
<td>Patil and Lotery60</td>
<td>Case report</td>
<td>1</td>
<td>Topical CAIs Depo-Medrone Parabulbar Anti-VEGF IVT IVTA Cryotherapy</td>
<td>I DEX</td>
<td>10 months NR</td>
<td>From 1.01 logMAR to 6 weeks: 0.89 logMAR</td>
<td>From 559 µm to 6 weeks: 271 µm</td>
<td>None</td>
<td>2 IOP rise</td>
</tr>
</tbody>
</table>

**Abbreviations:** BCVA, best corrected visual acuity; CAIs, carbonic anhydrase inhibitors; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone acetonide; LE, left eye; NR, not reported; NSAIDs, nonsteroidal anti-inflammatory drugs; RE, right eye; TA, triamcinolone acetonide; VEGF, vascular endothelial growth factor.
## Table 8 Published studies on the use of DeX implant for other conditions

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>No of eyes</th>
<th>Previous treatment</th>
<th>Primary treatment</th>
<th>Follow-up</th>
<th>Retreatment</th>
<th>BCVA</th>
<th>CMT</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furino et al[1]</td>
<td>Retrospective</td>
<td>8 PPv + ILM peeling + cataract surgery</td>
<td>Diclofenac sodium and betamethasone drops</td>
<td>DEX</td>
<td>6.75±0.71 month</td>
<td>NR</td>
<td>From 20/50 to 20/23 P&lt;0.00001</td>
<td>From 438±45 µm to 296±49 µm P&lt;0.00001</td>
<td>No eye IOP &gt;18 mmHg</td>
</tr>
<tr>
<td>Taney et al[2]</td>
<td>Retrospective</td>
<td>5 PPv with ERM peeling</td>
<td>Topical prednisolone 1% Topical NSAIDs Subtenon TA IVTA in 1 eye Anti-VEGF IVT in 3 eyes Anti-VEGF IVT 1 eye</td>
<td>DEX</td>
<td>NR</td>
<td>3 Snellen lines improvement in 3 eyes at 4–6 weeks after DEX 9 DEX in 1 eye 7 DEX in 1 eye</td>
<td>Mean CMT decrease of 106 µm (range 56–155 µm) in 4 eyes at 4–6 weeks after DEX</td>
<td>1 eye IOP &gt;25 mmHg Cataract in 1 out of the 2 phakic eyes</td>
<td></td>
</tr>
<tr>
<td>Merkoudis and Granstam[3]</td>
<td>Case report</td>
<td>1 PPv + ILM peeling and C3F8 tamponade + cataract surgery</td>
<td>IVTA Topical NSAIDs Oral CAI Anti-VEGF IVT</td>
<td>DEX</td>
<td>10 months</td>
<td>NR</td>
<td>From 20/200 to 2 months: 20/40</td>
<td>Reduction of CMT 2 months after DEX</td>
<td>None</td>
</tr>
<tr>
<td>Georgalas et al[4]</td>
<td>Case report</td>
<td>1 PPv + ILM peeling cataract surgery</td>
<td>Topical steroids Subtenon steroids Intravitreal steroids</td>
<td>DEX</td>
<td>6 months</td>
<td>NR</td>
<td>From counting fingers to 1 week: 6/36</td>
<td>From 640 µm to 1 week: 383 µm</td>
<td>None</td>
</tr>
<tr>
<td>Bonfiglio et al[5]</td>
<td>Case report</td>
<td>1 scleral buckling + cryopexy</td>
<td>Oral prednisolone Oral CAI Topical prednisolone Topical NSAIDs TA Subtenon</td>
<td>DEX</td>
<td>6 months</td>
<td>NR</td>
<td>From 0.70 to 6 months: 0.20 logMAR</td>
<td>From 510 µm to 6 months: 290 µm</td>
<td>None</td>
</tr>
</tbody>
</table>

**Abbreviations:** BCVA, best corrected visual acuity; CAI, carbonic anhydrase inhibitor; CMT, central macular thickness; DEX, dexamethasone implant; ERM, epiretinal membrane; ILM, inner limiting membrane; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone; NR, not reported; NSAIDs, nonsteroidal anti-inflammatory drugs; PPV, pars plana vitrectomy; TA, triamcinolone acetonide; VEGF, vascular endothelial growth factor.
**DEX implant in macular edema after retinal surgery**

DEX implant was used also in case of macular edema secondary to PPV for epiretinal membrane or macular hole or scleral buckling (Table 8). In all cases, an anatomical and functional improvement was shown, even though in 2 cases, multiple DEX implants were performed because of recurrent macular edema. Additionally, the use of DEX allowed resolution of severe choroidal inflammation detected in 1 case following scleral buckle surgery.

**Conclusion**

The use of DEX implant for all of the aforementioned macular pathologies merits consideration, and the results reported can support the use of DEX implant on a case-by-case basis with the aim of improving patient outcomes in many macular pathologies.

In many of these cases, DEX implant allowed a reduction of CMT with an improvement of BCVA, even if, at long term, many eyes required retreatment because DEX implant started to lose its efficacy, sometimes at 3 months after the injection.

Many of these cases were refractory to previous treatments, and DEX implant was administered as the last treatment option. Consequently, the functional results provided may be influenced by the lateness of DEX implant use. Therefore, considering that many of the reported macular pathologies may be difficult to treat and that some of them are not especially uncommon, having an awareness of a new treatment option and its influence on the clinical course of the disease may represent a great assistance in clinical practice. Furthermore, the use of DEX remains the only solution in treating macular edema in vitrectomized eyes where the efficacy of other IV drug injections, such as anti-VEGF, is lost due to their pharmacokinetic properties.

DEX implant-related adverse events in this expanding-use scenario are consistent with those previously documented for the DEX treatment of diabetic macular edema, uveitis, and retinal vein occlusion. In the cases that we analyzed, cataract was reported in up to 33% of the eyes after 2 DEX implants, and the occurrence of ocular hypertension (IOP ≥25 mmHg) from 6% to 31%, all treated with topical therapy.

In conclusion, DEX implant may allow less frequent anti-VEGF treatment and therefore, the advantages for the patient are clear: the need to undergo stressful treatment is removed while ocular and systemic adverse effects are reduced.

**Acknowledgments**

We thank Ray Hill, an independent medical writer, who provided English-language editing and journal styling before submission on behalf of Health Publishing & Services Srl. Technical editing and publication fees for this manuscript were supported by Allergan.

**Author contributions**

All authors contributed to developing the concepts, design, and/or analysis and interpretation of data in this review, writing/revising the manuscript, and approved the final version before submission and agreed to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


